linjc16/ctgov huggingface dataset:
Assessment of Clinical Trial Experiences of Alzheimer's Disease Patients

Study Overview
=================
Brief Summary
-----------------
Taking part in medical trials usually favors a particular demographic group. But there is limited research available to explain what trial attributes affect the completion of these specific demographic groups. This study will admit a wide range of data on the clinical trial experience of Alzheimer's Disease patients to determine which factors prevail in limiting a patient's ability to join or finish a trial. It will also try to analyze data from the perspective of different demographic groups to check for recurring trends which might yield insights for the sake of future Alzheimer's Disease patients.

Official Title
-----------------
In Depth Observational Clinical Trial Assessing Experiences of Alzheimer's Disease Patients To Determine Trial Attributes Affecting Completion Rates For Specific Demographic Groups

Conditions
-----------------
Alzheimer Disease

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient is at least 50 to 80 years of age Participant has a diagnosis of Alzheimer's Disease Patient has self-identified as planning to enroll in an interventional clinical trial for Alzheimer's Disease Exclusion Criteria: No diagnosis of Alzheimer's Disease confirmed Inability to perform regular electronic reporting Patient does not understand, sign, and return consent form

Ages Eligible for Study
-----------------
Minimum Age: 50 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Rate of patients who decide to enroll in a Alzheimer's Disease Clinical Trial |  | 3 months | 
| Number of patients who remain in Alzheimer's Disease clinical trial until completion |  | 12 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Alzheimer Disease, Alzheimer's
Can we Use a Simple Blood Test to Reduce Unnecessary Adverse Effects From Radiotherapy by Timely Identification of Radiotherapy-resistant Rectal Cancers? MeD-Seq Rectal Study

Study Overview
=================
Brief Summary
-----------------
Chemoradiation therapy (CRT) followed by surgery is currently the standard of care to treat patients with locally advanced rectal cancer (LARC). CRT reduces local recurrences, but is associated with significant damage to the surrounding healthy tissue that can severely impact quality of life. Additionally, a proportion of patients (hardly) benefit from CRT. We aim to develop a diagnostic innovation, which can enable a more selective and thereby more effective use of the available therapies for rectal cancer patients. The objective of this study is to investigate whether patients can be identified who will response to CRT prior to start of the CRT in rectal cancer and therefore avoid possible severe side effects in patients who will not reponse on CRT.

Official Title
-----------------
Can we Use a Simple Blood Test to Reduce Unnecessary Adverse Effects From Radiotherapy by Timely Identification of Radiotherapy-resistant Rectal Cancers? MeD-Seq Rectal Study

Conditions
-----------------
Pathological Response Rate, Circulating Tumour DNA

Intervention / Treatment
-----------------
* Diagnostic Test: MeD-seq


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age ≥18 years Histologically confirmed rectal adenocarcinoma Scheduled for neoadjuvant chemoradiation Written informed consent. Exclusion Criteria: Scheduled to another neoadjuvant schedule that comprises systemic chemotherapy or short-course radiation Not able to read or understand Dutch language or mentally not capable.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Diagnostic Test: MeD-seq|MeD-seq analyse: DNA treatment bisulfite --> unmethylated C-nucleotide trabsformed in uracil.--> PCR --> next generation sequencing (NGS) --> localization methylated nucleotides (enzym LpnPI).|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| cfDNA methylation markers |  | 4 years |
The Lumbar Trident Study

Study Overview
=================
Brief Summary
-----------------
This observational retrospective study evaluates the efficacy of RF with the three-tined expandable electrode needle compared to before treatment in the treatment of chronic lumbar facet joint pain.

Official Title
-----------------
Lumbar Facet Joint Denervation With a Trident Electrode, a Retrospective Observational Study

Conditions
-----------------
Facet Joint Pain

Intervention / Treatment
-----------------
* Procedure: Radiofrequency denervation of the lumbar facet joint


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age > 18 years old Patients with lumbar pain Patient who had two diagnostic medial branch blocks with significant (>50%) improvement on both injections Exclusion Criteria: - No patient related outcome measures available in hospital's patient charts

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 99 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: Radiofrequency denervation of the lumbar facet joint|Radiofrequency denervation of the medial branch of the dorsal ramus of the lumbar facet joint with a three-tined expandable needle.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pain measurement by numeric rating score | The primary outcome of this study is pain measured with the numeric rating score (NRS): 11-point NRS ranging from 0 (no pain at all) to 10 (the worst imaginable pain). A score of zero (0) will indicate that the patient is pain free, while a score of ten (10) will indicate that they are experiencing the worst pain imaginable. | 2 months after injection in comparison to baseline | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Patient Global Impression of Change (PGIC) | The PGIC rating is increasingly being used for determining clinically important change in measures such as ratings of pain. This scale is designed to quantify patient's improvement or deterioration over time, usually either to determine the effect of an intervention or to chart the clinical course of a condition. The scales ask that a person assess his or her current pain, recall that status at a previous time-point, and then calculate the difference between the two. | 2 months after injection | 
| Use of analgesics | The quantity of analgesics that the patient assumes for the pain: All stopped Decreased Equal Increased | 2 months after injection | 
| Sleep | Question: your sleep quality is: Improved Equal Worsened | 2 months after injection | 
| Walking ability | Question: after the treatment, you can walk: More than before Same as before Less than before | 2 months after injection | 
| Patient satisfaction | Question: are you satisfied with the result: YES/NO | 2 months after injection |
A Community-Based Screening Program to Identify Participants at High Risk for Amyloid Pathology

Study Overview
=================
Brief Summary
-----------------
The primary purpose of this study is to identify participants with or without symptoms of Alzheimer's Disease (AD) that are at high risk for brain amyloid pathology using blood-based biomarkers.

Official Title
-----------------
A Community-Based Screening Program to Identify, Using Blood-Based Biomarkers, Individuals With or Without Alzheimer's Disease Symptoms Who Are at High Risk for Brain Amyloid Pathology

Conditions
-----------------
Alzheimer's Disease

Intervention / Treatment
-----------------
* Other: No Intervention


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Male or female, age 50 to 80 years inclusive, at the time of informed consent - Those 50 to 64 years of age must have 1 of the following risk factors confirmed prior to blood sample collection: First degree relative with dementia onset before age 75, Known before screening to have at least 1 Apolipoprotein E4 (APOE4) allele, or Known before screening to have elevated brain amyloid according to previous positron emission tomography (PET), cerebrospinal fluid (CSF), or blood testing Provide written informed consent Willing and able to comply with all aspects of the protocol Willing to be referred to a clinical site if the assessment results meet the criteria Exclusion Criteria: Known uncontrolled medical conditions (example, cardiac, respiratory, gastrointestinal, psychiatric, renal disease, malignant neoplasm) Participation in an interventional clinical trial study at the time of consent

Ages Eligible for Study
-----------------
Minimum Age: 50 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| All Participants<br>Participants with or without symptoms of AD will be enrolled and observed in this study. | Other: No Intervention<br>* No treatment intervention will be administered.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of Participants With Low, Medium, and High Amyloid Pathology | Number of participants with low, medium, and high amyloid pathology will be estimated. | At Screening on Day 1 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Alzheimers Disease, Blood-based biomarkers, Community-based screening
Adenoid Vegetations in Adult Patients

Study Overview
=================
Brief Summary
-----------------
In this observational cross-sectional study  the clinical characteristics of adenoid vegetations in adulthood will be investigated.

Detailed Description
-----------------
Adenoid vegetations typically appear in childhood and are well described in this population. However, in adulthood, adenoid vegetations appear rarely and their characteristics have not been described. The clinical characteristics of adenoid vegetations in adulthood will be investigated, and compared with clinical characteristics of adenoid vegetations in childhood.

Official Title
-----------------
The Clinical Characteristics of Adenoid Vegetations in Adult Patients

Conditions
-----------------
Adenoid Vegetation

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patient with adenoid vegetations Exclusion Criteria: other concomitant otorhinolaryngological diagnoses hypertrophy of the tonsils oropharyngeal carcinomas chronic sinuitis allergic rhinitis

Ages Eligible for Study
-----------------
Minimum Age: 1 Year
Maximum Age: 105 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Adults<br>Patients with adenoid vegetations, 14 years old and older | |
| Children<br>Patients with adenoid vegetations, 13 years old and younger | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Symptoms | The leading symptom (patient's main complaint, the reason for seeing the doctor) will we recorded for each participant | 2 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Duration of symptoms | The duration of leading symptom (in months) will be recorded for each participant | 2 months | 
| OTS (otoscopic) | The otoscopic findings will be recorded in both groups | 2 months | 
| RNS (rhinoscopic) | The rhinoscopic findings will be recorded in both groups | 2 months | 
| OFS (oropharyngoscopic) | The oropharyngoscopic findings will be recorded in both groups | 2 months | 
| PRNS (post-rhynoscopic) | The post-rhynoscopic findings will be recorded in both groups | 2 months | 
| Referring physician | The physician (primary or secondary level) who referred the patient to ENT (Ear Nose and Throat doctor) will be recorded in both groups | 2 months | 
| PHD ( pathohistological findings) | The pathohistological findings will be recorded in both groups | 2 months | 
| Surgery | The type of surgery will be recorded in both groups | 2 months | 
| Outcome | The outcome (the relief of the leading symptom) will be recorded in both groups | 2 months | 
| Recurrence | The recurrence will be recorded in both groups | 2 months |
Management of Aorto-iliac Infection With BioIntegral Surgical No-React® Bovine Pericardial Xenografts

Study Overview
=================
Brief Summary
-----------------
Aortic infections (AIs), including aortic graft infections (AGI) as well as mycotic aortic aneurysms (MAA), are rare. The aim of this study is to present our experience with xenogeneic aortic and aortoiliac reconstructions using the BioIntegral Surgical No-React® bovine pericardial graft.

Official Title
-----------------
Management of Aorto-iliac Infection With BioIntegral Surgical No-React® Bovine Pericardial Xenografts

Conditions
-----------------
Aortic Diseases

Intervention / Treatment
-----------------
* Procedure: Aortic Surgery


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Aortic infection Mycotic Aneurysm Aortic Graft Infection Exclusion Criteria: Absence of signs of infection

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: Aortic Surgery|open surgical repair with resection of infected aortic segment, debridement of surrounding tissue and in situ graft replacement.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Early Mortality | Mortality 30 days after the procedure | 30 days |
Neurosurgical Neuronavigation Using Resting State MRI and Machine Learning

Study Overview
=================
Brief Summary
-----------------
This study is investigating the use of a computer algorithm to analyze scans of the brain before surgery to predict how a person's tumor will respond to treatment.

Official Title
-----------------
Advancing Neurosurgical Neuronavigation Using Resting State MRI and Machine Learning - a Prospective Study

Conditions
-----------------
Glioblastoma Multiforme

Intervention / Treatment
-----------------
* Device: Support Vector Machine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Must be a new radiological diagnose of a lesion in the brain with characteristics consistent with glioblastoma multiforme. Diagnostic scan must have occurred no more than 1 month prior to enrollment. Must be planning to undergo a clinical MRI. Must be at least 18 years old. Must be able to understand and willing to sign an IRB approved written informed consent document. Exclusion Criteria: Contraindication to MRI. Previous surgery for a brain tumor. Inability to have clinical follow-up (e.g., patient is out of town and will do follow-up elsewhere).

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Standard of care rsfMRI using the Support Vector Machine algorithm<br>-Once enrolled, clinical pre-surgical MRI will be done on Siemens 3T Prisma or Skyra scanners using a standard pre-surgical tumor protocol. Resting-state functional MRI (rsfMRI) will be acquired. The Support Vector Machine (SVM) algorithm will be used on this pre-surgical MRI. | Device: Support Vector Machine<br>* Machine learning algorithm<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of participants who are deemed as short-term survivor or a long-term survivor | -Patients will be deemed as a short-term survivor or a long-term survivor and this will be defined as overall survival as less than or greater than 14.5 months, respectively. | Through completion of follow-up (estimated to be 2 years) |
Goal-directed Analgesia Using ANI During General Anesthesia in Children With Moyamoya Disease

Study Overview
=================
Brief Summary
-----------------
Analgesia Nociception Index (ANI) has been proposed for the evaluation of the nociception-antinociception balance in the perioperative period. In pediatric patients with Moyamoay disease, where the management of analgesia may be rendered difficult by pharmacological changes, we hypothesised that the monitoring of analgesia with ANI would reduce intraoperative opioid consumption during EDAS surgery.

Official Title
-----------------
Effect of Goal-directed Analgesia Using ANI (Analgesia/Nociception Index) During General Anesthesia in Children Undergoing EDAS (Encephaloduroarteriosynangiosis) Surgery for Moyamoya Disease: a Randomized Controlled Trial

Conditions
-----------------
Pain

Intervention / Treatment
-----------------
* Device: ANI (Analgesia/Nociception Index) monitoring
* Device: standard monitoring
* Drug: Sufentanil


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Pediatric patients receiving EDAS surgery for Moyamoya disease Exclusion Criteria: ASA (American society of anesthsiologists classification) 4-5 Emergency surgery patients with chronic pain on medication

Ages Eligible for Study
-----------------
Maximum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: ANI (Analgesia/Nociception Index) monitoring<br> | Device: ANI (Analgesia/Nociception Index) monitoring<br>* Intraoperative analgesia was provided by injection of sufentanil, which was performed according to ANI monitor.<br>Drug: Sufentanil<br>* Sufentanil<br>|
| Active Comparator: Standard monitoring<br> | Device: standard monitoring<br>* Intraoperative analgesia was provided by injection of sufentanil, which was performed according to the clinician's assessment.<br>Drug: Sufentanil<br>* Sufentanil<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| the mean hourly intraoperative sufentanil requirement |  | from induction of anesthesia to end of operation, about 5 hours | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| the amount of non-opioids analgesic requirements |  | from induction of anesthesia to end of operation, about 5 hours | 
| the amount of vasoactive agents requirements |  | from induction of anesthesia to end of operation, about 5 hours |
The Efficacy of Topical Serum X for Skin Brightening

Study Overview
=================
Brief Summary
-----------------
This study is conducted to evaluate the effectiveness of topical serum X containing arbutin and glutathione for skin brightening. The study duration is 12 weeks and the skin assessment will be carried out at baseline, week 4, 8 and week 12.The main questions this study aims to answer are: The skin brightening effect of the product on facial skin. To observe any adverse effect occurrence with the usage of the product.

Official Title
-----------------
The Efficacy of Topical Serum X Containing Arbutin and Glutathione for Skin Brightening

Conditions
-----------------
Healthy

Intervention / Treatment
-----------------
* Other: Other: Serum X


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Malaysia citizen Male and female (age 18-30 years old) Exclusion Criteria: Participant with severe acne skin condition Participant who is taking isotretinoin, immunocompromised patients and received laser and light treatment within the last three months Participant who undergo whitening or cosmetic treatments such as botox and dermal fillers within the previous six month Participant with a history of facial surgery such as facelift or nose reshaping Participant with history of allergies to any ingredient in the study product Participant who is pregnant or plan to get pregnant

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 30 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Serum X<br>Participants will used serum X twice daily for 12 weeks | Other: Other: Serum X<br>* Serum X contain arbutin and glutathione<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Changes in skin tone from baseline and at week 4, week 8, and week 12 after usage of serum X. | Skin tone will be assessed using JANUS III skin analyzer | Baseline and at week 4, week 8, and week 12 | 
| Adverse effect after using serum X | Based on adverse effect occurrence on participants that occur during study period (12 weeks | Week 12 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Aesthetic, Cosmetic